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Abstract 
Purpose: To investigate the expressions of S100 calcium-binding proteins A8 (S100A8) and S100 A9 
(S100A9) in nasopharyngeal carcinoma (NPC) tissues and their correlation with clinical pathological 
characteristics and prognosis of NPC.  
Methods: Ninety-two NPC tissue samples and 92 nasopharyngitis tissue samples (controls) were 
collected. All the NPC patients were on follow-up for more than 5 years. The expressions of S100A8 
and S100A9 were determined in these tissues by immunohistochemistry. The relationship between the 
expressions of S100A8 and S100A9, and the clinico-pathological features were analyzed by Spearman 
correlation analysis, and the results evaluated by Kaplan-Meier method. 
Results: The differences between their expressions in the two tissues were statistically significant (p < 
0.05). Neither gender nor age was associated with expressions of S100A8 and S100A9 (p > 0.05), but 
they were closely related to the degree of differentiation, clinical stages and metastasis of lymph node 
(p < 0.05). The expression of S100A8 had significant positive correlation with the expression of S100A9 
(r = 0.393, p = 0.000). Prognosis of patients with positive expressions of S100A8 and S100A9 was poor, 
when compared to patients with negative expressions of these proteins (p < 0.05). 
Conclusion: Expressions of S100A8 and S100A9 are closely related to the development of NPC. High 
expressions of the two proteins may have an important influence in the progress of tumor invasion but 
are associated with poor prognosis of NPC. These findings could be significant indicators of early 
diagnosis, effectiveness of treatment and prognosis of NPC. 
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Nasopharyngeal carcinoma (NPC) usually occurs 
on the top, or in the lateral wall of the 
nasopharynx. It is a malignant head and neck 
tumor associated with high incidence and fatality 
rate [1,2]. The primary treatment for NPC is 
radiation therapy, but the clinical effect of this 
therapy is not satisfactory because of high rate of 
local recurrence and metastasis. The survival 
rate of 5 years after treatment of patients in stage 
1 NPC may be up to 95 % after combined 
therapy, but the survival rate of 5 years after 
treatment for stage Ⅳ patients is merely 35 % 
[3]. Thus, it is important to improve early 
diagnosis and search for new therapeutic targets 
and prognostic indicators of NPC. 
 
S100 proteins belong to the family of calcium- 
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binding proteins with low molecular weight. All 
members of this family have special spatial 
structures that enable them bind calcium ions, 
and are involved in signal transduction [4,5]. 
S100 calcium-binding protein A8 and S100 
calcium-binding protein A9 genes are 
both located on the long arm of chromosome 1 
(1q21) with the characteristic helical annular and 
EF-hand structures of S100 protein family [6]. 
However, chromosomal deletions, translocations 
and overlaps are more common due to weak 
stability of this bond of chromosome [7]. S100A8 
is an active pro-inflammatory calcium binding 
protein composed of 267 bases encoding 88 
residues. S100A9 exhibits various biological 
activities such as regulation of cell growth and 
proliferation, protein phosphorylation, 
inflammatory reactions and cell migration [8,9].  
 
Studies in recent years have reported that 
S100A8 and S100A9 are implicated in the 
pathogenesis and development of tumors, 
especially in metastasis of tumor cells and 
induction of immune suppression [10-12]. 
However S100A8 and S100A9 have different 
functions and modes of action in different tumor 
cells. Moreover the exact roles of the two 
proteins in NPC have not been elucidated.  
 
In this study, the expressions of S100A8 and 
S100A9 in NPC were measured by 
immunohistochemistry. The data were analyzed 
for any correlation with clinical pathological 






NPC tissue samples of 92 patients were 
collected in the Head and Neck Surgery unit of 
the Department of Otolaryngology, Renmin 
Hospital of Wuhan University, and Department of 
Oncology in Central Hospital of Huangshi City of 
Edong Healthcare, from January 2008 to 
December 2011. The study was approved by 
Ethics Committee of The Renmin Hospital of 
Wuhan University, (approval no. WH200170024), 
and followed the guidelines of Declaration of 
Helsinki promulgated in 1964 as amended in 
1996 [13]. All the patients agreed to participate in 
this study and signed informed consent. There 
were 58 males and 34 females, who aged from 
22 to 67 years (mean age = 50.76 ± 9.42 years). 
There were 74 cases of low differentiation and 18 
cases of middle or high differentiation. Based on 
2008 UICC/AJCC staging standards, 48 cases 
were in stages I and II, while 44 cases were in 
stages III and IV. Lymph node metastasis 
occurred in 63 cases, but was absent in 29 
cases. In addition, 92 chronic nasopharyngitis 
tissue samples were collected at the same 
period, as control. There were 55 males and 37 
females in the control group, aged from 21 to 65 
years (mean age = 50.42 ± 9.36 years). The 
differences between baseline data of the two 
groups showed no statistical significance (p > 
0.05).  
 
Inclusion and exclusion criteria 
 
The inclusion criteria included patients diagnosed 
by MRI/CT and pathological examination, 
patients who were not on radiation therapy or 
chemotherapy, or any other form of treatment; 
patients with KPS scores ≥ 70, and patients with 
complete clinical and pathological data.  
 
Patients with a history of other organ tumors, 
patients diagnosed with serious heart, brain, lung 
and kidney diseases, pregnant or breastfeeding 
patients, and patients who were unwilling to 





NPC tissue samples were fixed in 10 % 
methanol, paraffin-embedded, sectioned and 
then de-waxed. The tissue biopsies were placed 
in boiling citric acid buffer (pH 6.0), and heated 
continuously for 15 min by microwave to repair 
the antigen, incubated in the deionized water of 3 
% hydrogen peroxide for 15 min at 37 oC. The 
first antibodies (rabbit anti-human S100A8 and 
S100A9 monoclonal antibodies (Abcam 
Company, UK) were added, incubated for 60 min 
at 37 oC and incubated at 4 oC overnight. Then 
the second antibody (SP kit, Abcam Company, 
UK) was added, and incubated for 45 min at 37 
oC. Thereafter streptavidin-peroxidase (S-P) was 
added, and the complex was incubated for 45 
min at 37 oC, and stained with BAD, then again 
with hematoxylin. This positive tissue section 
was used as positive control, while in the 
negative control, the first antibody was replaced 
with citrate buffer.  
 
Expressions of S100A8 and S100A9 were 
located in cytoplasm and cell nucleus. Couple 
score and semi-ration score criterion were 
performed to evaluate the results. Ten (10) visual 
fields were randomly selected under 
optical microscope (x400) and 100 cells were 
sequentially counted for each field. The staining 
intensity of tumor cells and percentage of 
positive cells were evaluated, and positive 
expression was judged by the total score of 
staining intensity and positive cells. The scoring 
criteria for staining intensity were: 0 or 1 for pale 
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yellow, 2 for brownish-yellow, and 3 for tan. 
Positive cells were scored as follows: 0 for < 6 % 
positive cells; 1 for 6 - 25 % positive cells; 2 for 
26 - 50 % positive cells; 3 for 51 - 75 % positive 
cells; and 4 for > 75 % positive cells. The scores 
for staining intensity and positive cells were 
combined, and classified as follows: score of 0 - 
1 was negative expression (-); scores of 2 - 3 
were categorized as weakly positive expression 
(+); scores of 4 - 5 indicated mildly positive 
expression (++), while scores of 6 - 7 were 





Measurement data are expressed as mean ± 
standard deviation (SD) and t test was used for 
the comparison between means. The results 
from enumeration were expressed as percentage 
(%) and χ² test was used for the comparison. 
Data were analyzed statistically by SPSS 22.0 
software. Spearman correlation analysis was 
used to analyze association of the expressions of 
S100A8 and S100A9. Kaplan-Meier method was 
applied to analyze survival data. P < 0.05 





Comparison of expressions of S100A8 and 
S100A9 in NPC and nasopharyngitis tissues 
 
The positive expressions of S100A8 and S100A9 
were 52.17 and 72.83 %, respectively in NPC 
tissue, and 17.39 and 36.96, respectively in 
nasopharyngitis tissue (Table 1). The differences 
in the expressions of these proteins between the 
two tissues were statistically significant (p < 
0.05). 
 
Relationship between expressions of S100A8 
and S100A9, and clinical pathology  
 
Neither gender nor age was associated with the 
expressions of S100A8 and S100A9 (P > 0.05), 
but they had closely relation to the degree of 
differentiation, TNM system and lymph 
node metastasis (p < 0.05, Table 2). 
 
Table 1: Comparison of the expressions of S100A8 and S100A9 in NPC and nasopharyngitis tissues {(n (%)} 
 
Group No. of cases 
Expression of S100A8 Expression of S100A9 
- +～+++ - +～+++ 
NPC tissue 92 44(47.83) 48 (52.17) 25 (27.17) 67 (72.83) 
Nasopharyngitis tissue 92 76 (82.61) 16 (17.39) 58 (63.04) 34 (36.96) 
χ2 -  24.533  23.903 
P -  0.000  0.000 
 
Table 2: Relationship between the expressions of S100A8 and S100A9, and clinical pathology {n (%)} 
 




- +～+++ - +～+++  
Gender    0.565/0.452   0.136/0.712 
Male 58 26（44.83） 32（55.17）  15（25.86） 43（74.14）  
Female 34 18（52.94） 16（47.06）  10（29.41） 24（70.59）  
Age    2.630/0.105   1.620/0.203 
<60 years 38 22（57.89） 16 (42.11)  13（34.21） 25（65.79）  
≥60 years 54 22（40.74） 32 (59.62)  12（22.22） 42（77.78）  
Degree of 
differentiation    8.046/0.005   4.545/0.033 
Low differentiation 74 30（40.54） 44 (59.46）  16（21.62） 58（78.38）  
Middle or high 
differentiation 18 14（77.78） 4（22.22）  9（50.00） 9（50.00）  
TNM system    8.661/0.003   5.408/0.020 
Ⅰ~Ⅱ 48 30（62.50） 18（37.50）  18（37.50） 30（62.50）  
Ⅲ~Ⅳ 44 14（31.82） 30（68.18）  7（15.91） 37（84.09）  
Lymph 
node metastasis    10.260/0.001   12.898/0.000 
Yes 63 23（36.51） 40（63.49）  10（15.87） 53（84.13）  
No 29 21（72.41） 8（27.59）  15（51.72） 
14（48.28）  
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Correlation analysis of expressions of 
S100A8 and S100A9 in NPC tissues  
 
Spearman correlation analysis indicated that the 
expression of S100A8 was significantly and 
positively correlated with the expression of 
S100A9 (r = 0.393, p = 0.000, Table 3). 
 
Relationship between expressions of S100A8 
and S100A9, and prognosis 
 
All the patients were followed up for more than 5 
years. Based on the expressions of S100A8 and 
S100A9, the 92 patients were divided into 4 
groups, consisting of 20 cases of S100A8(-) and 
S100A9(-) which were placed in group A (1 case 
was lost during follow- up, while 19 cases 
completed follow-up); 24 cases of S100A8(-) and 
S100A9(+) were put in group B (2 cases were 
lost during follow-up, while 22 cases completed 
follow-up); 5 cases of S100A8(+) and S100A9(-) 
were placed in group C (no cases lost during 
follow-up); 43 cases of S100A8(+) and 
S100A9(+) were put in group D (5 cases lost to 
follow up, 38 cases completed follow up). The 
results of overall survival patients in each group 
are shown in Kaplan-Meier survival curves 
(Figure 1). Results (log-rank test) showed 
significant differences in survival time among the 
4 groups (χ2 = 10.336, p ＝ 0.016). Subsequently, 
Bonferroni’s test was used to compare the 
groups, and the results indicated that group A 
was significantly higher than group D (χ2 = 8.378, 
p ＝ 0.004), but no significant differences were 
seen between any other two groups (group A vs 
group B：χ2 = 1.937, p ＝ 0.164；group A vs 
group C：χ2 = 1.590, p ＝ 0.207；group B vs 
group C：χ2 = 0.250, p ＝ 0.617；group B vs 
group D：χ2 = 3.306, p ＝ 0.069；group C vs 




S100 proteins are small molecular weight 
calcium-binding proteins. S100A8 and S100A9 
are two monomeric proteins, encoded by genes 
located on chromosome 1q21 as part of the 
S100 gene cluster. Chromosome 1q21 is a 
region with poor stability due to chromosomal 
deletions, translocations and overlaps. Research 
has shown that the chromosomal changes in this 
region are closely related to incidence of cancer 
[14]. Under normal physiological conditions, 
S100A8 and S100A9 are secreted in the 
cytoplasm by myeloid cells such as monocytes, 
neutrophils and macrophages. 
 
 
Table 3: Correlation analysis of the expressions of S100A8 and S100A9 in NPC tissues 
 
Item S100A9（-） S100A9（+） Total 
S100A8（-） 20 24 44 
S100A8（+） 5 43 48 
Total 25 67 92 
 
 
Figure 1: Overall survival (OS) of patients as a function of expressions of S100A8 and S100A9 
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However, the two proteins can also be secreted 
by epithelia, keratinocytes and endotheliocytes 
under pathological conditions, and transferred to 
membranes, cytoskeletons or outside the cell 
[15,16]. 
 
Results from recent studies suggest that the 
expressions of S100A8 and S100A9 were up-
regulated in most malignant tumor cells, and are 
related to the formation, infiltration and 
metastasis of carcinoma [17]. In this study, the 
expressions of S100A8 and S100A9 in NPC 
tissue, and in chronic nasopharyngitis tissue was 
determined immunohistochemically. The results 
showed that these expressions were significantly 
higher in NPC than in nasopharyngitis tissues. 
Hermani et al [18] have reported that cell growth 
can be promoted by glycation end-products 
receptor (RAGE), a process which also activates 
the phosphorylation activity of mitogen-activated 
protein kinase (MAPK) and the pathway of 
nuclear factor-κB (NF-κB), thereby leading to cell 
proliferation. Thus, the increased expression of 
S100A8 and S100A9 in NPC tissues may induce 
tumor cell proliferation. 
 
Han et al [19] reported that the serum levels of 
S100A8 and S100A9 in NPC patients were 
significantly higher than those of healthy 
persons. Moreover, Kim et al [17] found 
significant increases in S100A8 and S100A9 in 
the plasma of patients with colorectal cancer, 
and suggested that these can serve as serum 
markers in the clinical diagnosis of colorectal 
cancer. This is in agreement with the results 
obtained in the present study which showed that 
S100A8 and S100A9 had closely correlation with 
the degree of differentiation, stage of TNM 
system and lymph node metastasis, indicating 
that the expressions of S100A8 and S100A9 
increase with the degree of malignancy of NPC. 
However, there was no close relationship 
between the expressions of S100A8 and 
S100A9, and the gender and age of the NPC 
patients. Studies by Lim et al.[20] showed that 
monocytes and macrophages in the 
microenvironment of metastatic liver cells 
induced the formation of S100A8 and S100A9, 
and that these two proteins influenced the 
migration and invasion of tumor cells. 
 
Results of correlation analysis in this study 
showed that the expression of S100A8 had low 
correlation with the expression of S100A9, which 
indicated that the two proteins may have 
synergistic effects on the formation and 
development of NPC. S100A8 and S100A9 form 
S100A8 -S100A9 heterodimer complex in a 
calcium-dependent process [21-23]. In the 
S100A8-S100A9 complex, S100A8 is the main 
bioactive protein, while S100A9 serves to ensure 
the stability of the complex by regulating S100A8 
[24,25]. The results of survival analysis (Kaplan-
Meier) also indicated a synergy in the 
expressions of S100A8 and S100A9. The 
prognosis of patients with positive expressions of 
S100A8 and S100A9 was poorer than that of 
patients with negative expressions of S100A8 
and S100A9. This suggests that S100A8 and 
S100A9 genes can be used as predictors of 
prognosis of nasopharyngeal carcinoma.  
 
Through gene expression profiling, Moon et al 
[26] reported that S100A8 and S100A9 genes 
were potential indicators of the metabolic state of 
mammary epithelial cells, which can be potential 
targets for treating breast cancer and predicting 
prognosis. Results obtained by Wang et al [11] 
suggested that increased levels of myeloid-
derived suppressor cells (MDSCs) from bone 
marrow were closely related to increased clinical 
incidence of gastric cancer, and declines in 
survival rate. S100A8 and S100A9 could be 
potential indicators of immunosuppressive 
function induced by MDSCs of cancer patients. 
In this study, the expressions of S100A8 and 
S100A9 (for negative survival rate) showed no 
significant difference with positive survival rate of 
expression of either protein. However the 
survival curves showed distinct differences in 




The expressions of S100A8 and S100A9 in NPC 
tissues are fairly high. The expression of the two 
proteins are also positively correlated with 
severity of NPC, and thus indicate poor 
prognosis of the disease. These findings suggest 
that S100A8 and S100A9 could be significant 
indicators of early diagnosis, treatment 
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